Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Sultana, Rebeka ^a   Abdel Fatah, Tarek ^b   Perry, Christina ^a   Moseley, Paul ^b   Albarakti, Nada ^a   Mohan, Vivek ^a   Seedhouse, Claire ^a   Chan, Stephen ^b   Madhusudan, Srinivasan ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINO 4 CYCLOHEXYLMETHOXY 5 NITROSOPYRIMIDINE; ATR PROTEIN; CISPLATIN; DNA; FLUORESCEIN ISOTHIOCYANATE; GAMMA HISTONE H2AX; HISTONE H2AX; LIPOCORTIN 5; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VE 821; XRCC1 PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CHO CELL; CLONOGENIC ASSAY; COMET ASSAY; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; NONHUMAN; OVARY CANCER; PROTEIN DEFICIENCY;

ANIMALS; BASE SEQUENCE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DNA-BINDING PROTEINS; ENZYME INHIBITORS; FEMALE; HUMANS; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING;

EID: 84874521969     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057098     Document Type: Article

References (35)

1. Friedberg EC, (2003) DNA damage and repair. Nature 421: 436-440.
2. Siddik ZH, (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279.
3. Rabik CA, Dolan ME, (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23.
4. Nouspikel T, (2009) DNA repair in mammalian cells: Nucleotide excision repair: variations on versatility. Cell Mol Life Sci 66: 994-1009.
5. Shuck SC, Short EA, Turchi JJ, (2008) Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Res 18: 64-72.
6. Svilar D, Goellner EM, Almeida KH, Sobol RW, (2011) Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. Antioxid Redox Signal 14: 2491-2507.
7. Robertson AB, Klungland A, Rognes T, Leiros I, (2009) DNA repair in mammalian cells: Base excision repair: the long and short of it. Cell Mol Life Sci 66: 981-993.
8. Ladiges WC, (2006) Mouse models of XRCC1 DNA repair polymorphisms and cancer. Oncogene 25: 1612-1619.
9. Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, et al. (2008) XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res 18: 48-63.
10. Caldecott KW, (2003) XRCC1 and DNA strand break repair. DNA Repair (Amst) 2: 955-969.
11. Wilson DM, 3rd, Kim D, Berquist BR, Sigurdson AJ (2011) Variation in base excision repair capacity. Mutat Res 711: 100-112.
12. Corso G, Marrelli D, Pedrazzani C, Machado JC, Mancini S, et al. (2009) Gastric cardia carcinoma is associated with the promoter-77T>C gene polymorphism of X-ray cross-complementing group 1 (XRCC1). J Gastrointest Surg 13: 2233-2238.
13. Gossage L, Madhusudan S, (2007) Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther 11: 361-380.
14. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, et al. (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22: 2594-2601.
15. Kim K, Kang SB, Chung HH, Kim JW, Park NH, et al. (2008) XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol 111: 509-515.
16. Sun X, Li F, Sun N, Shukui Q, Baoan C, et al. (2009) Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 65: 230-236.
17. Abdel-Fatah T, Sultana R, Abbotts R, Hawkes C, Seedhouse C, et al. (2012) Clinicopathological and functional significance of XRCC1 (X-ray repair cross-complementing gene 1) expression in ovarian cancer. Int J Cancer. doi: 10.1002/ijc.27980.
18. Cimprich KA, Cortez D, (2008) ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 9: 616-627.
19. Nam EA, Cortez D, (2011) ATR signalling: more than meeting at the fork. Biochem J 436: 527-536.
20. Toledo LI, Murga M, Fernandez-Capetillo O, (2011) Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol 5: 368-373.
21. Chen T, Stephens PA, Middleton FK, Curtin NJ, (2012) Targeting the S and G2 checkpoint to treat cancer. Drug Discov Today 17: 194-202.
22. Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, et al. (2011) Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer 105: 372-381.
23. Cliby WA, Lewis KA, Lilly KK, Kaufmann SH, (2002) S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem 277: 1599-1606.
24. Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, et al. (2004) DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol 66: 478-491.
25. Lord CJ, Ashworth A, (2008) Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 8: 363-369.
26. Banerjee S, Kaye SB, Ashworth A, (2010) Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol 7: 508-519.
27. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG, (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10: 293-301.
28. Berquist BR, Singh DK, Fan J, Kim D, Gillenwater E, et al. (2010) Functional capacity of XRCC1 protein variants identified in DNA repair-deficient Chinese hamster ovary cell lines and the human population. Nucleic Acids Res 38: 5023-5035.
29. Caldecott KW, Tucker JD, Thompson LH, (1992) Construction of human XRCC1 minigenes that fully correct the CHO DNA repair mutant EM9. Nucleic Acids Res 20: 4575-9.
30. Fan J, Wilson PF, Wong HK, Urbin SS, Thompson LH, et al. (2007) XRCC1 down-regulation in human cells leads to DNA-damaging agent hypersensitivity, elevated sister chromatid exchange, and reduced survival of BRCA2 mutant cells. Environ Mol Mutagen 48: 491-500.
31. Sultana R, McNeill DR, Abbotts R, Mohammed MZ, Zdzienicka MZ, et al. (2012) Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int J Cancer 131: 2433-44.
32. Berenbaum MC, (1981) Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 35: 269-335.
33. Serrano MA, Li Z, Dangeti M, Musich PR, Patrick S, et al. (2012) DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair. Oncogene.
34. Sirbu BM, Lachmayer SJ, Wulfing V, Marten LM, Clarkson KE, et al. (2012) ATR-p53 restricts homologous recombination in response to replicative stress but does not limit DNA interstrand crosslink repair in lung cancer cells. PLoS One 6: 1-10.
35. Zhang R, Niu Y, Zhou Y, (2010) Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol Lett 192: 108-14.